GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mind Medicine Inc (NAS:MNMD) » Definitions » Cash per Share

MNMD (Mind Medicine) Cash per Share : $3.62 (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Mind Medicine Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Mind Medicine's Cash per Share for the quarter that ended in Sep. 2024 was $3.62.

Mind Medicine Cash per Share Historical Data

The historical data trend for Mind Medicine's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mind Medicine Cash per Share Chart

Mind Medicine Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Cash per Share
3.92 4.75 3.74 2.43

Mind Medicine Quarterly Data
Sep19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.94 2.43 3.55 3.37 3.62

Mind Medicine Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Mind Medicine's Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=99.704/41.10
=2.43

Mind Medicine's Cash per Share for the quarter that ended in Sep. 2024 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=295.284/81.59
=3.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mind Medicine  (NAS:MNMD) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Mind Medicine Cash per Share Related Terms

Thank you for viewing the detailed overview of Mind Medicine's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Mind Medicine Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mind Medicine Inc (NAS:MNMD) » Definitions » Cash per Share
Comparable Companies
XERS IMTX PGEN ANAB ABSI MGTX TECX ORIC MRVI OMER VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
MMQ:Germany
Address
One World Trade Center, Suite 8500, New York, NY, USA, 10007
Website
https://www.mindmed.co
Mind Medicine Inc is a biopharmaceutical company. The company produces to treat brain health disorders. The company discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances. The firm is having an approach towards developing the next generation of psychedelic-inspired medicines and therapies.
Executives
Mark Sullivan officer: Chief Legal Officer 1000 BISHOPS GATE BOULEVARD, SUITE 300, MOUNT LAUREL NJ 08054
Robert Barrow director, officer: Chief Executive Officer C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007
Dan Karlin officer: Chief Medical Officer C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007
Carrie Liao officer: VP, Controller&Acct Principal C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007
David W Gryska director 749 N MARY AVE, SUNNYVALE CA 94085
Schond L. Greenway officer: Chief Financial Officer C/O CERECOR, INC., 540 GAITHER ROAD, SUITE 400, ROCKVILLE MD 20850
Carol A Vallone director 490 SUMMER STREET, MANCHESTER MA 01944
Andreas Krebs director 5 GIRALDA FARMS, MADISON NJ 07940
Suzanne Louise Bruhn director C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746
Roger Crystal director 445 PARK AVE, 10TH FL., NEW YORK NY 10022
Cynthia W. Hu officer: Chief Legal Officer&Secretary 6440 WINDERMERE, NORTH BETHESDA MD 20852
Brigid Makes director 20245 SW 95TH AVENUE, TUALATIN OR 97062
Sarah Y Vinson director C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007
Stephen L Hurst director C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007
Miri Halperin Wernli director, officer: Executive President C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007